Fig. 2: The expression of PCAT5 and its efects on glycolysis, proliferation migration and invasion in EC.

A lncRNA microarray was performed to detect the gene profile when LIN28B was knockdown in the EC cells (n = 3 per group). B, C RT-qPCR was performed to detect the lncRNA expression of PCAT5, DLEU2, H19 and NBAT1 when LIN28B was knockdown in the EC cells (n = 3). D FISH and IF double staining was performed to detected the binding effects between LIN28B and PCAT5 in EC cells (n = 3) Scar bar = 25 μm. E Expression of PCAT5 in TCGA cohort of endometrial tissues, tumor (n = 552), compared with normal endometrial tissue (n = 35). F Effect of PCAT5 expression level on EC patient survival time from TCGA database. G ROC of PCAT5 (TCGA cohort). H The PCAT5 expression levels in the EC (n = 50) and control (n = 49) group were detected by RT-qPCR. I–K The effects of PCAT5 overexpression or silencing on the HK2 and PKM2 expression in EC cells was assessed by RT-qPCR (n = 3). L–N The effects of PCAT5 overexpression or silencing on the HK2 and PKM2 expression in EC cells was assessed by western blot (n = 3). O–Q The effects of PCAT5 overexpression or silencing on the glycolysis ability in EC cells was assessed by ECAR (n = 3). R, S The effects of PCAT5 overexpression or silencing on the proliferation ability in EC cells was assessed by EdU assay (n = 3), Scar bar = 50 μm. T, U The effects of PCAT5 overexpression or silencing on the migration ability in EC cells was assessed by wound-healing assay (n = 3), Scar bar = 100 μm. V, W The effects of PCAT5 overexpression or silencing on the transwell ability in EC cells was assessed by transwell assay (n = 3), Scar bar = 50 μm. Data are expressed as means ± standard deviation. *p < 0.05; **p < 0.01; ***p < 0.001.